0000000000007425

AUTHOR

Stefania Principe

showing 16 related works from this author

Sleep Disturbances in COPD are Associated with Heterogeneity of Airway Obstruction

2018

Individuals with Chronic Obstructive Pulmonary Disease (COPD) experience sleep disturbances due to the impact of respiratory symptoms on sleep quality. We explored whether sleep disturbances in COPD are linked to heterogeneity of airway constriction.The impact of breathing problems on sleep quality was measured in consecutive COPD outpatients with the COPD and Asthma Sleep Impact Scale (CASIS) questionnaire. Impulse oscillometry technique (IOS) was employed to assess heterogeneity of airway constriction. Subjects with a previous or concomitant diagnosis of asthma or obstructive sleep apnea (OSA) were excluded.Fifty COPD subjects (M/F 40/10; age: 71 +/- 8 yrs, Body Mass Index (BMI): 26.2 +/-…

sleep abnormalitieMaleSleep Wake DisordersPulmonary and Respiratory Medicinemedicine.medical_specialtyPulmonary diseaseCASISSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineForced Expiratory VolumeOscillometrySurveys and QuestionnairesInternal medicinemedicineCOPDHumansSleep Wake DisorderOximetry030212 general & internal medicineRespiratory systemOxyhemoglobinAgedIOSCOPDSleep qualitybusiness.industryMiddle AgedAirway obstructionmedicine.diseaseSleep in non-human animalsSleep abnormalitiesResidual Volume030228 respiratory systemOxyhemoglobinsCardiologyFemalebusinessHumanCOPD: Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Fever and dyspnoea in a tracheostomised patient

2020

A 65-year-old man was referred for evaluation of acute onset of fever, productive cough and dyspnoea. He had previously received a diagnosis of laryngeal carcinoma, which had been treated with laryngectomy and bilateral laterocervical lymphadenectomy, followed by chemotherapy. He underwent plastic surgery of the laryngocutaneous fistula, and a positron emission tomography (PET)- computed tomography (CT) examination performed during follow-up showed 18-FDG (2-fluoro-2-deoxyd- glucose) lung uptake in the apical right portion. He had a smoking history and his regular medications included dexamethasone, metoclopramide, omeprazole, furosemide, cholecalciferol and pregabalin. He had a history of …

lcsh:RC705-779Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industrylung fibrosisMEDLINECase Reportlcsh:Diseases of the respiratory systemtomographySettore MED/10 - Malattie Dell'Apparato RespiratorioExpert Opinionoilrespiratory tract diseases18Emergency medicineMedicinebusiness
researchProduct

Are biological drugs effective and safe in older severe asthmatics?

2019

Introduction: The treatment of asthma in older ages follows the recommendations of international guidelines for the management of asthma in younger ages, although older age has always represented an exclusion criterion for eligibility to pharmacological trials. This poses a clinical challenge when deciding whether elderly severe asthmatics are candidates for biological drugs. Areas covered: The current article has a narrative structure to review the current literature on efficacy and safety of novel pharmacological drugs against immunoglobulins and interleukins that mediate and orchestrate the main inflammatory pathways in severe asthma, in order to explore whether older subjects (i.e. >…

medicine.medical_specialtypulmonary eosinophilia/drug therapyeducationImmunoglobulinsmonoclonal030204 cardiovascular system & hematologySettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentSeverity of Illness IndexBiological drugs03 medical and health sciences0302 clinical medicineimmune system diseasesInternal medicineSeverity of illnessImmunoglobulinHumansMedicineAnti-Asthmatic AgentPharmacology (medical)Age FactorAnti-Asthmatic AgentsAsthmaAgedRandomized Controlled Trials as TopicBiological ProductsAsthma/drug therapybiologyhumanizedbusiness.industryInterleukinsAge FactorsGeneral MedicineInterleukinmedicine.diseaseAsthmarespiratory tract diseasesantibodie030220 oncology & carcinogenesisMonoclonalPractice Guidelines as Topicbiology.proteinBiological Productanti-asthmatic agents/pharmacologyAntibodybusinessHuman
researchProduct

Compliance to ventilatory treatment in a cohort of patients on home CPAP or NIV: analysis by diagnosis, treatment type, and comorbidities

2019

Background: Patients on home continuous positive airway pressure (CPAP) or noninvasive ventilation (NIV) show large variability in compliance to treatment. Aim: To identify predictors of poor compliance, we evaluated compliance to treatment in patients with obstructive sleep apnea (OSA), obesity hypoventilation syndrome (OHS), and OSA-chronic obstructive pulmonary disease (COPD) overlap syndrome. Methods: We analyzed clinical and compliance data provided by a single home care provider, in 602 patients (n=442 OSA, males (M) 308; 38 OHS M=15, and 122 overlap M=111) on home CPAP/NIV in the province of Agrigento, Italy, after one year of treatment. The following variables were considered: age, …

Obesity hypoventilation syndromeCOPDmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentOverlap syndromePressure support ventilationmedicine.diseaserespiratory tract diseasesObstructive sleep apneaInternal medicineCohortmedicineContinuous positive airway pressurebusinessBody mass indexSleep and control of breathing
researchProduct

The impact of SARS-COV2 pandemic on the management oF IPF patients: Our narrative experience

2021

Abstract Background The SARS-CoV-2 pandemic has changed the health-care systems around the world in a remarkable way. We describe the strategies adopted to cope with the limitations imposed by the pandemic to the access to health care by patients diagnosed with idiopathic Pulmonary Fibrosis (IPF). Material and methods We conducted a retrospective observational analysis including IPF patients under antifibrotic drugs (nintedanib and pirfenidone) that accessed to the Outpatient clinic of the University of Palermo, Italy. Patients received a phone number and an email address in case of any urgency and a virtual meeting was settled up monthly. Results 40 patients (M/F: 30/10) were followed up, …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPyridonesCOVID-19 IPF Pulmonary fibrosis SARS-CoV-2DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioSARS-CoV-2 severe acute respiratory syndrome coronavirus 2ArticlePulmonary fibrosis03 medical and health sciencesIdiopathic pulmonary fibrosischemistry.chemical_compound0302 clinical medicineED Emergency departmentInternal medicinePulmonary fibrosisPandemicmedicineOutpatient clinicHumansPharmacology (medical)030212 general & internal medicineIPF Idiopathic Pulmonary FibrosisPandemicsRetrospective StudiesCOVID-19 Coronavirus disease 2019business.industrySARS-CoV-2Biochemistry (medical)ARDS adult respiratory distress syndromeCOVID-19Emergency departmentPirfenidonemedicine.diseaseIdiopathic Pulmonary FibrosisIPF030228 respiratory systemchemistryHRCT High-resolution chest tomographyRNA ViralNintedanibbusinessPulmonary fibrosimedicine.drug
researchProduct

The potential role of SP-D as an early biomarker of severity of asthma

2021

Surfactant decreases the surface tension of peripheral airways and modulates the immunological responses of the lung. The alterations of surfactant due to the airway inflammation suggest a role in the pathogenesis of asthma. We aim to test the hypothesis that serum levels of SP-A (Surfactant Protein A) and SP-D (Surfactant Protein-D) are altered in patients with mild asthma compared to healthy controls and those alterations are related to functional abnormalities of peripheral airways, which are an early marker of progression of asthma. In this pilot study, we recruited 20 mild asthmatics and 10 healthy controls. We measured serum SP-A and SP-D and all subjects underwent clinical, lung func…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyprecision medicinePilot ProjectsSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPathogenesisPulmonary surfactantInternal medicinemedicineHumansIn patientAsthmasmall airwaysLungbusiness.industryasthmaPulmonary Surfactant-Associated Protein Dmedicine.diseaserespiratory tract diseasesPeripheralSurfactant protein Amedicine.anatomical_structureBreath TestsBiomarker (medicine)businessBiomarkersJournal of Breath Research
researchProduct

Relationship between sleep disturbances and peripheral airway abnormalities in COPD patients

2017

Background: Individuals with COPD experience sleep disturbances due to the impact of symptoms on quality of sleep. Aim: To test the hypothesis that, in COPD, sleep disturbances are linked to peripheral airway abnormalities. Methods: An investigational study is being performed at the University of Palermo, Italy. The impact of breathing problems on quality of sleep during the previous week is measured with the COPD and Asthma Sleep Impact Scale (CASIS) questionnaire. Airway resistances by impulse oscillometry (IOS) assesses peripheral airway abnormalities. Lung function evaluation includes static and dynamic lung volume measurements. To rule out the risk of having obstructive sleep apnea, th…

medicine.medical_specialtyCOPDbusiness.industryAirway obstructionmedicine.diseaseAir trappingInterim analysisrespiratory tract diseasesObstructive sleep apneaImpulse OscillometryInternal medicinemedicineCardiologymedicine.symptomAirwaybusinessAsthmaClinical Problems Asthma
researchProduct

Exhaled metabolite patterns to identify recent asthma exacerbations

2021

Asthma is a chronic respiratory disease that can lead to exacerbations, defined as acute episodes of worsening respiratory symptoms and lung function. Predicting the occurrence of these exacerbations is an important goal in asthma management. The measurement of exhaled breath by electronic nose (eNose) may allow for the monitoring of clinically unstable asthma and exacerbations. However, data on its ability to perform this is lacking. We aimed to evaluate whether eNose could identify patients that recently had asthma exacerbations. We performed a cross-sectional study, measuring exhaled breath using the SpiroNose in adults with a physician-reported diagnosis of asthma. Patients were randoml…

exhaled breath; eNose; asthma; exacerbationexacerbationexhaled breathEndocrinology Diabetes and MetabolismAsthma ENose Exacerbation Exhaled breathSettore MED/10 - Malattie Dell'Apparato RespiratorioasthmaMolecular BiologyBiochemistryMicrobiologyeNoseQR1-502Article
researchProduct

Management of suspected COVID-19 patients in a low prevalence region

2020

The spread of the SARS-CoV-2 infection among population has imposed a re-organization of healthcare services, aiming at stratifying patients and dedicating specific areas where patients with suspected COVID-related respiratory disease could receive the necessary health care assistance while waiting for the confirmation of the diagnosis of COVID-19 disease. In this scenario, the pathway defined as a “grey zone” is strongly advocated. We describe the application of rules and pathways in a regional context with low diffusion of the infection among the general population in the attempt to provide the best care to respiratory patients with suspected COVID-19. To date, this process has avoided t…

MaleRespiratory Tract DiseasesDiseaseClinical Laboratory Technique0302 clinical medicineCOVID-19 TestingHealth carePrevalence030212 general & internal medicinehealth-care managementeducation.field_of_studyrespiratory symptomsOrganizational InnovationGrey zoneCritical PathwayItalyCritical PathwaysFemaleCoronavirus InfectionsHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationPneumonia ViralContext (language use)Settore MED/10 - Malattie Dell'Apparato RespiratorioDiagnosis Differential03 medical and health sciencesBetacoronavirusmedicineHumansIntensive care medicineeducationPandemicsAgedrespiratory symptomInfection ControlBetacoronavirubusiness.industryCoronavirus InfectionClinical Laboratory TechniquesSARS-CoV-2Hot TopicCOVID-19Patient Care ManagementCOVID-19 Drug Treatment030228 respiratory systemEpidemic outbreakbusinessChronic Respiratory Disease
researchProduct

The influence of smoking status on exhaled breath profiles in asthma and COPD patients

2021

Breath analysis using eNose technology can be used to discriminate between asthma and COPD patients, but it remains unclear whether results are influenced by smoking status. We aim to study whether eNose can discriminate between ever- vs. never-smokers and smoking &lt

MaleCopd patientsPharmaceutical ScienceeNoseAnalytical ChemistryPulmonary Disease Chronic Obstructive0302 clinical medicineDrug DiscoveryElectronic Nose0303 health sciencesCOPDConfoundingfood and beveragesMiddle AgedBreath Testsexhaled breathChemistry (miscellaneous)ExhalationMolecular MedicineSmoking statusFemaleAdultmedicine.medical_specialtySmoking habitPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioArticlesmokinglcsh:QD241-44103 medical and health scienceslcsh:Organic chemistryInternal medicinemedicineHumansCOPDPhysical and Theoretical Chemistry030304 developmental biologyAsthmaVolatile Organic Compoundsbusiness.industryfungiOrganic Chemistryasthmamedicine.diseaserespiratory tract diseasesCross-Sectional Studies030228 respiratory systemBreath gas analysisROC CurveAsthma COPD eNose Exhaled breath SmokingCase-Control Studiesbusiness
researchProduct

Severe asthma and COVID-19: lessons from the first wave

2020

Objective: Severe asthma is considered a risk factor for SARS-Coronavirus 2 (SARS-CoV-2) infection but scientific evidences are lacking. Methods: we performed a literature search and review based on PubMed database national, international recommendations as well as papers on severe asthmatic patients and their management during SARS-CoV-2 pandemic. Results: the majority of international recommendations, expert panels and editorials provide indications about management of severe asthmatic patients. No published studies evaluated the effects of biologic agents on severe asthmatic patients during SARS-CoV-2 pandemic. Conclusions: the relationship between SARS-CoV-2 and asthma is variable world…

Pulmonary and Respiratory Medicinesevere asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)biologic agentsvirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaInhaled corticosteroidsSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroids03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansImmunology and AllergyAnti-Asthmatic AgentsPediatrics Perinatology and Child Health030212 general & internal medicineRisk factorskin and connective tissue diseasesPandemicsAsthmabusiness.industryAsthma; biologic agents; COVID-19; inhaled corticosteroids; oral corticosteroids; SARS-CoV-2; severe asthmaSARS-CoV-2fungiPatient AcuityAsthma biologic agents COVID-19 inhaled corticosteroids oral corticosteroids SARS-CoV-2 severe asthmaCOVID-19medicine.diseaseAsthmarespiratory tract diseasesBiologic Agentsbody regions030228 respiratory systemPractice Guidelines as TopicPediatrics Perinatology and Child Healthinhaled corticosteroidsbusiness
researchProduct

Treating severe asthma:Targeting the IL‐5 pathway

2021

Abstract Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)‐4, IL‐5 and IL‐13). Monoclonal antibodies that target the eosinophilic inflammatory pathways (IL‐5R and IL‐5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for severe eosinophilic asthma. Eosinophils threshold represents the most indicative biomarker for response to treatment with all three monoclonal antibodies. Improvement in asthma symptoms scores, lung function, the number of exacerbations, history of late‐o…

0301 basic medicineImmunologyReview ArticleDisease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineReslizumabEosinophilicHumansImmunology and AllergyMedicineInvited ReviewsAnti-Asthmatic AgentsInterleukin 5Asthmabusiness.industryAnti-Asthmatic Agents Asthma Eosinophils Interleukin-5medicine.diseaseBenralizumabAsthmaEosinophils030104 developmental biology030228 respiratory systemchemistryImmunologyBiomarker (medicine)Interleukin-5businessMepolizumabmedicine.drug
researchProduct

Urinary Incontinence in Chronic Obstructive Pulmonary Disease: A Common Co-morbidity or a Typical Adverse Effect?

2019

Urinary incontinence (UI) is defined as a loss of bladder control and is characterized by the complaint of any involuntary leakage of urine. Evidence suggests that the prevalence of UI is higher in subjects with chronic obstructive pulmonary disease (COPD) than in age-matched controls in both sexes. UI is classified as stress, urge, and mixed, and has a considerable impact on quality of life. However, the prevalence of UI in individuals with COPD is mostly unexplored in clinical research and often underestimated in clinical practice. Interestingly, although the involuntary leakage of a small amount of urine during coughing (e.g., stress UI) is among the most plausible causes of UI in patien…

Malemedicine.medical_specialtyUrinary incontinenceAnticholinergic agentsComorbidity03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesPrevalenceMedicineHumansCOPDPharmacology (medical)030212 general & internal medicineAdverse effectbladderAgedCOPDbusiness.industryUrinary retentionmedicine.diseaseComorbidityClinical researchUrinary IncontinenceQuality of LifeFemaleGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Does the frequency of switching inhalers represent a predictive factor of exacerbation in asthma?

2020

Objective: Management of asthma includes monitoring of inhaler technique and level of adherence to treatment. Both factors could be influenced by high frequency of switching inhaler devices. We explored whether switching inhalers is an independent predictive factor of exacerbations. Methods: Data were collected from 2015 to 2017 from the outpatient clinic of asthma at the University of Palermo, Italy. This observational study consisted of two phases: Phase 1 included subjects of at least three visits in the previous year who reported the frequency of inhalers switched; Phase 2 included subjects of at least two visits during the second year, and the rate of switches and exacerbations was rec…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyExacerbationSettore MED/10 - Malattie Dell'Apparato Respiratorioexacerbation: inhaler03 medical and health sciencesYoung Adult0302 clinical medicineAdrenal Cortex HormonesAdministration InhalationmedicineImmunology and AllergyHumans030212 general & internal medicineAnti-Asthmatic AgentsIntensive care medicinedeviceAsthmaAgedAged 80 and overbusiness.industryInhalerNebulizers and VaporizersMiddle Agedmedicine.diseaseAsthmaswitchPredictive factorHospitalization030228 respiratory systemPediatrics Perinatology and Child Healthbusiness
researchProduct

Asthmatics with high levels of serum surfactant protein D have more severe disease.

2016

Pulmonary surfactant is a mixture of lipids and surfactant-specific proteins that covers the alveolar surface, as well as the terminal conducting airways, lowering the surface tension at the air–liquid interface during breathing. The involvement of pulmonary surfactant in the pathophysiology of asthma has been suggested. An interesting working hypothesis is that the surface tension of the peripheral airways is altered in asthma, because the inflammatory process affects the structure and function of surfactant, leading to excessive airway narrowing and features of air trapping. We explored whether serum levels of surfactant protein D (SP-D) in asthmatics are related to the severity of the di…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalesurfactantStatistics as TopicSevere diseasemacromolecular substancesSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineSeverity of illnessMedicineHumansAnti-Asthmatic Agentsbusiness.industrySmall airwaysSurfactant protein DReproducibility of Resultsrespiratory systemMiddle AgedPulmonary Surfactant-Associated Protein DAsthmaRespiratory Function Tests030104 developmental biology030228 respiratory systemImmunologyBiomarker (medicine)FemalebusinessBiomarkersThe European respiratory journal
researchProduct

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics

2019

Background: Healthcare decisions made on the basis of insufficient evidence may potentially have ineffective or even harmful consequences. The proportion of older ages (over 65 years) in randomized controlled trials (RCTs) for severe asthma is not enough to establish whether anti-IL-5/IL-5R therapies are equally effective in the elderly as in younger subjects. Methods: In order to assess the relationship between age and the efficacy of anti-IL-5 monoclonal antibodies (mABs) with respect to the risk of exacerbations and changes in FEV1, a meta-regression analysis via random-effect method was carried out by plotting the effect estimates (outcome variables) resulting from the pairwise meta-ana…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. AllergymABs monoclonal antibodiesSevere asthmamedicine.medical_specialtyExacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioImmunologyPopulationEosinophilArticlelaw.invention03 medical and health scienceschemistry.chemical_compoundAge0302 clinical medicineReslizumabRandomized controlled triallawInternal medicineImmunology and AllergyMedicine030223 otorhinolaryngologyeducationAsthmaEos eosinophilseducation.field_of_studybusiness.industryyrs yearsAnti-IL5medicine.diseaseBenralizumabEosinophilsRCTs Randomized Controlled TrialsClinical trial030228 respiratory systemchemistryTherapybusinesslcsh:RC581-607Mepolizumabmedicine.drug
researchProduct